Lanthanoid Complex Capsules for MRI Contrast Agent Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents using GdDTPA and GdDOTA face stability issues and toxicity concerns, leading to nephrogenic systemic fibrosis, and there is a need for a more stable and safe GdDOTA-based agent with enhanced bioavailability and pharmacokinetics for effective MRI applications.
Innovation Solution
Development of hyperbranched polymer nanoparticles and nanocapsules incorporating Gd3+ or Eu3+ ions with DOTA derivatives, using charge pairing and crosslinking agents to form compact polymeric structures that can be used as multimodal imaging and drug delivery agents, with the ability to target specific tissues and enhance solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GdDTPA and GdDOTA are used as MRI contrast agents, then contrast enhancement is achieved, but stability issues and toxicity concerns arise leading to nephrogenic systemic fibrosis
Solution Approach 1:
The patent uses composite materials by combining GdDOTA complexes with solid lipid nanoparticles (SLNs). The SLN core provides a stable carrier that encapsulates the GdDOTA complex, creating a composite structure that enhances both stability and safety. The lipid-based matrix protects the gadolinium complex from degradation while maintaining MRI contrast enhancement properties.
Solution Approach 2:
The solid lipid nanoparticle acts as an intermediary between the GdDOTA complex and the biological system. The SLN serves as a protective carrier that modulates the interaction between the contrast agent and body tissues, reducing direct toxicity while maintaining imaging functionality. The nanoparticle matrix controls release and distribution, acting as a buffer that prevents harmful effects.
2Adaptability or versatility
If noble metal particles are used for imaging agents, then multifunctionality is achieved, but expense and slow clearance through hepatic pathway occur
Solution Approach 1:
The patent replaces expensive noble metal particles with biodegradable solid lipid nanoparticles that can be cleared more rapidly. The SLNs are designed to be metabolically stable during circulation but can be degraded and excreted through hepatic pathways, avoiding the persistent accumulation issues of noble metals. The lipid-based material serves as a disposable carrier that completes its function and is then cleared from the system.
Solution Approach 2:
The patent changes the material composition parameter from noble metals to solid lipids, fundamentally altering the clearance characteristics. This parameter change enables faster hepatic clearance while maintaining the ability to perform multiple functions (imaging, drug delivery, targeting) through the customizable SLN platform.
3Measurement precision
If Gd3+ ions are used as contrast agents, then MRI contrast enhancement is achieved, but nephrogenic systemic fibrosis risk increases
Solution Approach 1:
The patent extracts the Gd3+ ions from free ionic form and incorporates them into stable GdDOTA complexes within the SLN matrix. This extraction from free ionic state eliminates the direct risk of nephrogenic systemic fibrosis while preserving the MRI contrast enhancement capability. The gadolinium is sequestered in a protected environment that prevents harmful biological interactions.
Solution Approach 2:
The GdDOTA complex serves as an intermediary that bridges the contrast enhancement function and safety requirements. The macrocyclic DOTA ligand chelates the Gd3+ ion in a stable configuration that maintains magnetic properties for imaging while preventing direct interaction with biological tissues that would cause fibrosis. The SLN matrix provides an additional layer of protection and controlled release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting agents provide high contrast for MRI images, are biodegradable, and avoid the toxicity issues of free Gd3+ ions, allowing for safe and effective imaging and drug delivery, with the potential for rapid clearance and reduced risk of nephrogenic systemic fibrosis.
Implementation Method 1
Lanthanoid complexes encapsulated solid lipid nanoparticles, or lanthanoid-complex nanoparticles... an MRI imaging agent comprised of gadolinium complexes has recently been assembled on the surface of silver nanoparticles
Implementation Method 2
using charge pairing and crosslinking agents to form compact polymeric structures that can be used as multimodal imaging and drug delivery agents
Implementation Method 3
the subsurface/surface location of the contrast agent determines the degree to which proton spin relaxation of water is due to inner sphere, T1 relaxation (surface) or outer sphere T1 and T2, or susceptibility relaxation (subsurface)
Data Source
AI summary
The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.